Physician profile
Daniel Dicesare
NPI 1902859093
$1,307.53
in general payments reported to CMS, 2019-2025
22 companies · $256 in 2025
The $256 reported for 2025 was less than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $512 · 2020: $71.14 · 2021: $136 · 2022: $169 · 2023: $139 · 2024: $24.34 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $419.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $287.73 | 2019-2025 | |
| Surgenex LLC | $149.59 | 2025 | Ardeograft, Pellograft, Surmatrix |
| Sun Pharmaceutical Industries INC. | $131.95 | 2019-2023 | Winlevi |
| Regeneron Healthcare Solutions, INC. | $98.76 | 2019-2020 | |
| Allergan, INC. | $83.88 | 2019-2022 | |
| Janssen Biotech, INC. | $83.09 | 2019-2023 | Simponi Aria, Stelara, Remicade |
| Pfizer INC. | $54.52 | 2021-2022 | |
| Amgen INC. | $53.44 | 2022-2023 | Otezla |
| Sandoz INC. | $42.99 | 2019 | |
| Epi Health, LLC | $40.94 | 2019 | |
| Dermira, INC. | $40.79 | 2019 | |
| Incyte Corporation | $33.61 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.32 | 2022 | |
| Vyne Pharmaceuticals INC. | $27.39 | 2020-2021 | |
| Genzyme Corporation | $24.34 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Prugen, INC. Pharmaceuticals | $24.14 | 2019 | |
| Celgene Corporation | $23.63 | 2019 | |
| Merck Sharp & Dohme LLC | $17.78 | 2019 | |
| Nabriva Therapeutics, Plc | $17.44 | 2021 | |
| Botanix Sb INC | $15.78 | 2025 | Sofdra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.17 | 2019 | |
| Lilly USA, LLC | $12.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Dicesare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.